Free Trial

Merus (MRUS) Stock Forecast & Price Target

Merus logo
$41.85 -0.24 (-0.57%)
(As of 12/20/2024 05:16 PM ET)

Merus - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
14

Based on 14 Wall Street analysts who have issued ratings for Merus in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 12 have given a buy rating, and 2 have given a strong buy rating for MRUS.

Consensus Price Target

$85.64
104.63% Upside
According to the 14 analysts' twelve-month price targets for Merus, the average price target is $85.64. The highest price target for MRUS is $109.00, while the lowest price target for MRUS is $67.00. The average price target represents a forecasted upside of 104.63% from the current price of $41.85.
Get the Latest News and Ratings for MRUS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Merus and its competitors.

Sign Up

MRUS Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
11 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$85.64$85.45$80.20$44.60
Forecasted Upside104.63% Upside87.85% Upside67.89% Upside64.76% Upside
Consensus Rating
Buy
Buy
Buy
Buy

MRUS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRUS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Merus Stock vs. The Competition

TypeMerusMedical CompaniesS&P 500
Consensus Rating Score
3.14
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside104.63% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent MRUS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/9/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$89.00 ➝ $97.00+121.76%
12/9/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$85.00 ➝ $85.00+90.37%
12/3/2024Guggenheim
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$111.00 ➝ $109.00+128.22%
12/2/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$85.00 ➝ $85.00+89.56%
11/21/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Law
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$73.00+70.04%
10/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00+37.64%
7/29/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/25/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$76.00 ➝ $76.00+35.52%
6/17/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $99.00+75.07%
6/4/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$84.00 ➝ $91.00+71.70%
6/4/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$69.00 ➝ $88.00+66.23%
4/22/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
8/21/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
4/17/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$35.00 ➝ $48.00+95.04%
4/14/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$35.00+41.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:52 PM ET.


MRUS Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Merus is $85.64, with a high forecast of $109.00 and a low forecast of $67.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRUS shares.

According to analysts, Merus's stock has a predicted upside of 104.63% based on their 12-month stock forecasts.

Merus has been rated by research analysts at Citigroup, Guggenheim, HC Wainwright, Needham & Company LLC, The Goldman Sachs Group, and UBS Group in the past 90 days.

Analysts like Merus more than other "medical" companies. The consensus rating for Merus is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRUS compares to other companies.


This page (NASDAQ:MRUS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners